cytarabine has been researched along with busulfan in 182 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (26.37) | 18.7374 |
| 1990's | 49 (26.92) | 18.2507 |
| 2000's | 31 (17.03) | 29.6817 |
| 2010's | 39 (21.43) | 24.3611 |
| 2020's | 15 (8.24) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Botnick, LE; Hannon, EC; Hellman, S; Vigneulle, RM | 1 |
| Bocaccino, CA; Greenberger, JS; Moloney, WC; Szot, SJ | 1 |
| Barabash, G; Benjamin, D; Djaldetti, M; Douer, D; Pinkhas, J; Weinberger, A | 1 |
| Chu, BC; Lawley, PD | 1 |
| Raposa, T | 1 |
| Fleischer, J | 1 |
| Botnick, LE; Hannon, EC; Hellman, S | 1 |
| Marsh, JC | 1 |
| Brodsky, I; Conroy, JF; Fuscaldo, KE; Kahn, SB; Lamping, CG | 1 |
| Blau, HJ | 1 |
| Millard, RE; Okell, SF | 1 |
| Brunner, K; Dear, KB; Haurani, F; Holland, JF; Karanas, A; Silver, RT; Weil, M | 1 |
| Copelan, EA | 1 |
| Russell, S; Vowels, M | 1 |
| Chandler, C; Devine, S; Geller, RB; Larson, RA; Myers, S; O'Toole, K; Park, CL; Topper, RL; Williams, SF | 1 |
| Cronin, S; Dan, ME; de Planque, MM; Karanes, C; Leisz, MC; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J | 1 |
| Masauji, N; Matsue, K; Tohi, T; Tsukuda, K | 1 |
| Mandelli, F; Meloni, G | 1 |
| Anderson, H; Chang, J; Deakin, DP; Heron, D; Morgenstern, GR; Oppenheim, B; Ranson, MR; Ryder, D; Scarffe, JH | 1 |
| Nagata, K; Nara, N; Suzuki, T; Tohda, S | 1 |
| Ehrsson, H; Eksborg, S | 1 |
| Freireich, EJ; Gutterman, J; Kantarjian, HM; Keating, MJ; Kurzrock, R; McCredie, KB; Talpaz, M | 1 |
| Fleischhauer, D; Gassmann, W; Loeffler, H; Müller-Ruchholtz, W; Uharek, L; Wottge, HU | 1 |
| Cavelli, F; Degnan, TJ; Holland, JF; Mick, R; Silver, RT | 1 |
| Gassmann, W; Löffler, H; Mueller-Ruchholtz, W; Schmitz, N; Uharek, L; Wottge, HU | 1 |
| Fernandez, LA; Zayed, E | 1 |
| Jacobs, P | 1 |
| Ballesta, F; Cervantes, F; Milá, M; Rozman, C | 1 |
| Gomis, F; Javier Rafecas, F; Lorenzo, IJ; Martín-Aragonés, G; Martínez, JA; Marty, ML; Sanz, GF; Sanz, MA; Sayas, MJ | 1 |
| Bligham, G; Freireich, EJ; Gehan, E; Hester, JP; Kantarjian, HM; Keating, MJ; McCredie, KB; Smith, TL; Talpaz, M; Walters, RS | 1 |
| Green, GI; Levin, RL; Pierce, LE; Witorsch, P | 1 |
| Tange, T | 1 |
| Chanana, AD; Cronkite, EP; Giacomelli, G; Greenberg, ML; Schiffer, LM; Stryctmans, PA; Vincent, PC | 1 |
| Garg, SK; Silber, R | 1 |
| Ishizaki, M; Kinoshita, H; Kitajima, K; Nagao, T; Takahashi, I | 1 |
| Boggs, DR; Chervenick, PA; Hyde, EF; Pan, SF; Srodes, CH | 1 |
| Gee, TS; Grabstald, H; Schreibman, SM | 1 |
| Canellos, GP; O'Connell, M; Rosenoff, SH; Wiernik, PH | 1 |
| Crowther, D | 1 |
| Baroncelli, PG; Cordero di Montezemolo, L; Madon, E; Roberi, PL; Sacerdote, A | 1 |
| Hunstein, W | 1 |
| Berndt, H; Rieche, K | 1 |
| Bollag, W | 1 |
| Nakamura, T; Sawada, H; Shirakawa, S; Todo, A; Yoshida, Y | 1 |
| Lamerton, LF | 1 |
| White, LP | 1 |
| Rachmilewitz, B; Rachmilewitz, M | 1 |
| Maurice, PA | 1 |
| Clifford, P; Klein, G; Singh, S; Stjernswärd, J | 1 |
| Lohrmann, HP; Schreml, W | 1 |
| Spiers, AS | 1 |
| Bennett, J; Golomb, H; Higby, D; Kirshner, J; Preisler, HD; Raza, A; Richman, C; Weiner, R; Winton, L; Woll, J | 1 |
| Kikuchi, Y; Yamamoto, KI | 1 |
| Fischer, P; Haas, O; Paietta, E; Schwarzmeier, JD | 1 |
| Ogier, C; Reizenstein, P | 1 |
| Stuart, J | 1 |
| Davidson, TG; Dix, SP; Geller, RB; Gilmore, CE; Holland, HK; Lin, LS; Topping, DL; Wingard, JR | 1 |
| Limper, AH; Rosenow, EC | 1 |
| Allen, PD; Castenskiold, EC; Coldwell, RD; Collins, PW; Goldstone, AH; Kelsey, SM; Makin, HL; Newland, AC; Side, LE | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R | 1 |
| Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D | 1 |
| Baybordi, E; Ghavamzadeh, A; Jahani, M | 1 |
| Attal, M; Brousset, P; Dastugue, N; Demur, C; Duchayne, E; Rigal-Huguet, F; Robert, A; Rubie, H | 1 |
| Abella, E; de Planque, MM; Eisenbrey, AB; Karanes, C; Lum, LG; Ratanatharathorn, V; Ravindranath, Y; Schultz, KR; Sensenbrenner, LL; Uberti, JP | 1 |
| Kantarjian, HM; Talpaz, M | 1 |
| Sipila, PE; Wiebe, VJ | 1 |
| Dohmen, M; Freund, M; Grote-Metke, A; Hild, F; Kleine, HD; Koch, O; Link, H; Nowak, R; Otremba, B; Wörmann, B | 1 |
| Baron, BW; Baron, JM; Mick, R | 1 |
| Devine, SM; Geller, RB; Holland, HK; Saral, R; Wingard, JR | 1 |
| Ferrara, J; Hellman, S; Hemman, S; Mauch, P; Montgomery, M; Neben, S | 1 |
| Barnett, MJ; Connors, JM; Klingemann, HG; O'Reilly, SE; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ | 1 |
| Leone, G; Pagano, L; Sica, S; Voso, MT | 1 |
| Ikeda, H; Inoue, T; Masaoka, T; Murayama, S; Ohtani, M; Shibata, H; Song, C; Tang, JT; Teshima, T; Yamazaki, H | 1 |
| Grande, M | 1 |
| Heinemann, V; Jehn, U; Pötscher, C | 1 |
| Crowther, D; Deakin, DP; Harris, M; Morgenstern, GR; Pettengell, R; Radford, JA; Ryder, D; Scarffe, JH; Wilkinson, PM; Woll, PJ | 1 |
| Davidson, TG; Devine, SM; Dix, SP; Geller, RB; Gilmore, CE; Heffner, LT; Hillyer, CD; Holland, HK; Jerkunica, I; Lin, LS; Mullins, RE; Saral, R; Wingard, JR; Winton, EF; York, RC | 1 |
| Bandini, G; Belardinelli, A; Fiacchini, M; Geromin, A; Gherlinzoni, F; Manfroi, S; Mangianti, S; Miggiano, MC; Motta, MR; Ricci, P; Rizzi, S; Rosti, G; Testoni, N; Tura, S; Visani, G | 1 |
| Cortes, JE; Kantarjian, H; Talpaz, M | 1 |
| Chiusolo, P; Di Mario, A; Leone, G; Micciulli, G; Salutari, P; Sica, S; Tommasi, M | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R | 1 |
| Akamatsu, M; Ikuno, Y; Nagatoshi, Y; Okamura, J; Tasaka, H | 1 |
| Urabe, A | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K | 1 |
| Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B | 1 |
| Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC | 1 |
| Corrado, C; Desmery, P; Dignani, C; Fernández, I; Juni, M; Martinez Rolón, J; Michelet, M; Milone, G; Pavlovsky, S | 1 |
| Badri, N; Boogaerts, M; Carella, AM; Dabouz-Harrouche, F; Gautier, L; Gorin, NC; Lennard, A; Link, H; Simonsson, B; Tomas-Martinez, JF | 1 |
| Chalmers, EA; Clark, RE; Crotty, G; Franklin, IM; Goldstone, AH; Hepplestone, A; Kelsey, SM; McBride, N; McCann, SR; Newland, AC; Sharp, RA; Singer, IO; Sproul, AM; Tansey, PJ; Watson, W | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
| Brice, P; Brion, A; Casassus, P; Dreyfus, F; Fenaux, P; Gratecos, N; Guerci, A; Hoang-Ngoc, L; Janvier, M; Jouet, JP; Leleu, X; Lepelley, P; Maloisel, F; Rochant, H; Solary, E; Wattel, E | 1 |
| Guilhot, F | 1 |
| Andreesen, R; Meidenbauer, N; Obermann, E; Reichle, A; Zeltner, R | 1 |
| Alvarez Román, MT; Canales Albendea, MA; Hernández Navarro, F; Villanueva Pavón, R | 1 |
| Brodsky, I; Case, D; Crilley, P; Damon, LE; Linker, CA; Navarro, W; Ries, CA; Rubin, A; Rugo, HS; Sayre, P; Topolsky, D; Wolfe, JL; Zamkoff, K | 1 |
| Cavenagh, JD; Kelsey, SM; Lillington, DM; McBride, NC; Murrell, C; Newland, AC | 1 |
| Achour, E; Azar, N; Belanger, C; Cassoux, N; Delattre, JY; Gerber, S; Hoang-Xuan, K; Leblond, V; Levy, V; Ribrag, V; Soussain, C; Suzan, F | 1 |
| Bieri, S; Chapuis, B; Helg, C; Miralbell, R | 1 |
| Brunstein, CG; Mcglave, PB | 1 |
| Kashyap, A; Snowden, J | 1 |
| Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C | 1 |
| Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM | 1 |
| Arellano-Rodrigo, E; Carreras, E; Cervantes, F; Espinet, B; Hernández-Boluda, JC; Lloveras, E; Marín, P; Montserrat, E; Ocejo, A; Rovira, M; Solé, F | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Case, D; Damon, LE; Linker, CA; Navarro, WA; Ries, CA; Wolf, JL | 1 |
| Clark, AD; Cook, G; Douglas, KW; Franklin, IM; McQuaker, IG; Mitchell, LD; Parker, AN; Tansey, PJ | 1 |
| Ault, P; Cortes, J; Kaled, ES; Kantarjian, H; Koller, C | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Burnett, AK; Chang, J; Chopra, R; Ewing, JC; Kell, WJ; Morgenstern, GR; Robertson, JD; Ryder, D; Scarffe, JH | 1 |
| Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
| Hoang-Xuan, K; Levy, V; Soussain, C | 1 |
| Berlier, P; Berthier, JC; Bertrand, Y; Bleyzac, N; Bruno, B; Contamin, B; Dai, QY; David, M; Galambrun, C; Homole, E; Manel, AM; Massenavette, B; Pages, MP; Philippe, N; Souillet, AL; Souillet, G | 1 |
| Horvath, N; Keefe, D; Lees, J | 1 |
| Antonenko, EV; Cherepovich, VS; Grinëv, VV; Lotkova, ES; Shakhlevich, EV | 1 |
| Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Drize, N; Nifontova, I; Petrova, T; Svinareva, D | 1 |
| Casasnovas, O; Choquet, S; Dupriez, B; Fourme, E; Gisselbrecht, C; Hoang-Xuan, K; Jaccard, A; Janvier, M; Kolb, B; Leblond, V; Omuro, A; Sanson, M; Souleau, B; Soussain, C; Taillandier, L; Taksin, AL; Witz, F; Zini, JM | 1 |
| Baer, MR; Baldus, CD; Bloomfield, CD; Caligiuri, MA; Carroll, AJ; Kolitz, JE; Langer, C; Larson, RA; Maharry, K; Marcucci, G; Mrózek, K; Paschka, P; Powell, BL; Ruppert, AS; Whitman, SP; Zhao, W | 1 |
| Bai, CH; Kim, YD; Song, SY; Woo, HJ | 1 |
| Acebo, E; Díaz-Pérez, JL; García-Ruiz, JC; Izu, R; Martínez de Lagrán, Z; Pérez-Barrio, S | 1 |
| Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Abidi, M; Abrams, J; Atallah, E; Ayash, L; Bentley, G; Ratanatharathorn, V; Uberti, J | 1 |
| Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C | 1 |
| Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C | 1 |
| Bruns, I; Czibere, A; Fenk, R; Galonska, L; Germing, U; Groten, A; Haas, R; Kobbe, G; Kondakci, M; Saure, C; Schroeder, T; Weigelt, C; Zohren, F | 1 |
| Furuya, T; Ikeda, T; Inoue, M; Kaneda, H; Koshinaga, T; Maebayashi, T; Masuko, T; Mugishima, H; Ohashi, K; Sugito, K; Yagasaki, H | 1 |
| Angelopoulou, MK; Beris, P; Constantinou, N; Dervenoulas, J; Diamantopoulos, P; Dimopoulos, MA; Dimou, M; Economopoulou, C; Economopoulou, P; Efthimiou, A; Georgiou, G; Kalpadakis, C; Katsigiannis, A; Korkolopoulou, P; Kotsianidis, I; Kyrtsonis, MC; Levidou, G; Meletis, J; Panayiotidis, P; Pangalis, GA; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vassilakopoulos, TP | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Liu, QF; Meng, FY; Sun, J; Wei, YQ; Wu, MQ; Wu, XL; Xu, D; Yu, GP; Zhang, Y; Zhao, J | 1 |
| Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U | 1 |
| Andreadis, C; Giacomini, KM; Kubo, M; Matsuda, K; Mefford, JA; Percival, ME; Singh, N; Stecula, A; Takahashi, A; Witte, JS; Yang, K; Yee, SW | 1 |
| Chen, XH; Gao, L; Gong, Y; Zhang, C; Zhang, X | 1 |
| Kato, K; Matsumoto, K; Matsuyama, T; Yoshida, N | 1 |
| Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY | 1 |
| Bubalo, J; Carpenter, PA; Leather, HL; Majhail, N; Marks, DI; Perales, MA; Pidala, J; Savani, BN; Shaughnessy, P; Wingard, J | 1 |
| Berritta, D; Cupri, A; Fauci, AL; Leotta, S; Milone, G; Parisi, M; Spina, P; Tripepi, G | 1 |
| Armand, P; Ballen, KK; Barnes, J; Batchelor, T; Brezina, M; Chen, YB; Chi, AS; Curtis, M; Del Rio, C; Dietrich, J; Driscoll, J; Gertsner, ER; Hochberg, E; Hochberg, F; Jones, S; LaCasce, AS; Li, S; McAfee, SL; Nayak, L; Spitzer, TR | 1 |
| Chen, XC; Huang, XO; Li, JJ; Liu, T; Liu, ZG; Lu, ZP; Tang, Y | 1 |
| Abrey, LE; Baser, RE; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, CC; Kaley, TJ; Matasar, MJ; Moskowitz, CH; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Sauter, CS | 1 |
| Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X | 1 |
| Abela, EM; Anagnostopoulos, A; Apostolou, C; Baliakas, P; Batsis, I; Douka, V; Iskas, M; Kaloyannidis, P; Karypidis, K; Konstantinou, V; Kouvatseas, G; Mallouri, D; Marvaki, A; Sakellari, I; Smias, C; Sotiropoulos, D; Yannaki, E | 1 |
| Fan, X; Hu, J; Tang, W; Wang, L | 1 |
| Ding, K; Geng, L; Liu, H; Qiang, P; Song, K; Sun, Z; Tang, B; Tong, J; Wang, X; Yao, W; Zhang, L; Zhang, X; Zheng, C; Zhu, X | 1 |
| Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF | 1 |
| Ding, KY; Geng, LQ; Han, YS; Liu, HL; Liu, X; Sun, ZM; Tang, BL; Tong, J; Wan, X; Wang, XB; Wang, ZY; Wu, JS; Wu, Y; Yang, HZ; Yao, W; Zhang, L; Zhang, XH; Zheng, CC; Zhu, WW; Zhu, XY | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Bittenbring, J; Ganser, A; Hallek, M; Huynh, A; Kröger, N; Labopin, M; Malard, F; Michallet, M; Mohty, M; Nagler, A; Savani, BN; Schmid, C; Stuhler, G; Tischer, J | 1 |
| Armand, P; Batchelor, TT; Chen, YB; DeFilipp, Z; El-Jawahri, A; Li, S; Nayak, L; Wang, N | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
| Cheng, H; Fei, X; Gu, J; He, J; Tian, Z; Wang, J; Wang, X; Xue, S; Yang, F; Yang, Y; Yin, Y; Zhang, S; Zhang, W; Zhao, J | 1 |
| Chen, J; Chen, L; Cheng, H; Gao, L; Hu, XX; Li, HM; Luo, YR; Ni, X; Song, XM; Tang, GS; Wang, JM; Wang, ZW; Xia, XX; Yang, D; Yang, JM; Zhang, WP; Zhou, H | 1 |
| Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X | 1 |
| Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q | 1 |
| Alexis, M; Amorim, S; Bay, JO; Chauchet, A; Chrétien, ML; Cluzeau, T; Contentin, N; Cornillon, J; Daguenet, E; de Latour, RP; Dorvaux, V; Gyan, E; Himberlin, C; Huynh, A; Lejeune, C; Mercier, M; Nicolas-Virelizier, E; Salles, G; Vallet, N | 1 |
| Jiang, P; Lu, Y; Ma, Q; Teng, S; Wang, H; Wang, J; Wu, D; Zhou, L; Zhu, X | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Bae, SH; Choi, Y; Jo, JC; Kim, IH; Kim, JS; Lee, JH; Lee, SM; Lee, WS; Lee, YJ; Lim, SN; Yoon, SS | 1 |
| Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Oniashvilli, N; Pasvolsky, O; Raanani, P; Rozovski, U; Rubinstein, M; Sela-Navon, M; Shargian-Alon, L; Wolach, O; Yahav, D; Yeshurun, M | 1 |
| Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K | 1 |
| Arai, Y; Atsuta, Y; Eto, T; Fukuda, T; Hirabayashi, S; Ichinohe, T; Ikegame, K; Kanda, J; Kawata, T; Kimura, T; Kondo, T; Marumo, A; Tabuchi, K; Tanaka, M; Uchida, N; Uozumi, R; Wake, A; Yanada, M; Yano, S | 1 |
| de Lima, VCC; Filho, JS; Germano, JN; Matias Vieira, GM; Moura, FL; Sapelli, J | 1 |
| Casper, J; Frietsch, JJ; Hilgendorf, I; Hochhaus, A; Köhne, CH; O'Hagan Henderson, S | 1 |
| Chen, J; Fan, S; Jiang, F; Liu, X; Liu, Z; Sun, Y; Xiao, J | 1 |
| Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S | 1 |
| Balsat, M; Barraco, F; Ducastelle-Leprêtre, S; Fossard, G; Ghesquières, H; Gilis, L; Hayette, S; Heiblig, M; Huet, S; Labussière-Wallet, H; Larcher, MV; Loron, S; Meur, GL; Michallet, M; Plesa, A; Renault, M; Sujobert, P; Thérèse, RM; Thomas, X; Tigaud, I | 1 |
| Fu, Y; Gui, R; Guo, S; Li, Z; Song, Y; Wang, X; Zhan, X; Zhang, B; Zhang, W; Zhang, Y; Zhou, J; Zu, Y | 1 |
| Baehring, JM; Kaulen, LD | 1 |
| Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ | 1 |
| Arcese, W; Ciceri, F; Gedde-Dahl, T; Gorin, NC; Labopin, M; Lanza, F; Maertens, J; Meijer, E; Mohty, M; Montoro, J; Pabst, T; Pérez-Simón, JA; Sanz, J; Schaap, N; Van Gorkom, G; Versluis, J; Vrhovac, R | 1 |
20 review(s) available for cytarabine and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Asparaginase; Benzamides; Busulfan; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Drug Evaluation, Preclinical; Erythrocytes; Fluorouracil; Hematopoietic Stem Cells; Humans; Hydroxyurea; Lomustine; Methotrexate; Nitrogen Mustard Compounds; Spleen; Vinca Alkaloids | 1976 |
Conditioning regimens for allogeneic bone marrow transplantation.
Topics: Anemia, Aplastic; Antilymphocyte Serum; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia; Lymphocyte Depletion; Melphalan; T-Lymphocytes; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
Drug level monitoring: cytostatics.
Topics: Alkylating Agents; Aminoacridines; Amsacrine; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bleomycin; Busulfan; Chlorambucil; Chromatography, Gas; Chromatography, Liquid; Cisplatin; Cyclophosphamide; Cytarabine; Fluorouracil; Humans; Mass Spectrometry; Melphalan; Methotrexate; Mitomycins; Monitoring, Physiologic; Nitrosourea Compounds; Podophyllotoxin; Purines; Thiotepa; Vinca Alkaloids | 1985 |
[Therapeutic considerations in chronic myeloid leukemia].
Topics: Busulfan; Chronic Disease; Cytarabine; Humans; Hydrocarbons, Brominated; Leukemia, Myeloid; Mannitol | 1974 |
[Biochemistry of antileukemic drugs].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Leukemia; Mannomustine; Mercaptopurine; Methotrexate; Vincristine | 1970 |
[Nucleic acid metabolism of leukemia cell].
Topics: Busulfan; Cytarabine; Dexamethasone; DNA; DNA, Neoplasm; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocytes; Mercaptopurine; Nucleic Acids; Prednisolone; Pyrimidines; RNA; RNA, Neoplasm | 1970 |
Cytotoxic drugs and the granulopoietic system.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Bone Marrow; Busulfan; Chlorambucil; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Cytotoxins; Dactinomycin; Fluorouracil; Granulocytes; Hematopoietic Stem Cells; Hematopoietic System; Humans; Methotrexate; Nitrogen Mustard Compounds; Nitrosourea Compounds; Vinblastine | 1982 |
Chronic granulocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Busulfan; Chromosomes, Human, 21-22 and Y; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Hydroxyurea; Leukapheresis; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Palliative Care; Prednisolone; Prednisone; Thioguanine; Vincristine | 1984 |
[Chromosome analysis and TdT determination: important prognostic parameters of blastic crises in chronic myelocytic leukemia].
Topics: Busulfan; Chromosome Aberrations; Cytarabine; DNA Nucleotidylexotransferase; DNA Nucleotidyltransferases; Humans; Hydroxyurea; Karyotyping; Leukemia, Myeloid; Prednisone; Prognosis; Thioguanine; Vincristine | 1982 |
Drug-induced pulmonary disease.
Topics: Amiodarone; Bleomycin; Busulfan; Cyclophosphamide; Cytarabine; Diagnosis, Differential; Humans; Immunocompetence; Immunocompromised Host; Lung Diseases; Mitomycins; Nitrosourea Compounds; Pneumonia | 1995 |
Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transplantation, Autologous; Transplantation, Homologous | 1994 |
Pharmacology of antineoplastic agents in pregnancy.
Topics: Abnormalities, Radiation-Induced; Antineoplastic Agents; Busulfan; Cyclophosphamide; Cytarabine; Embryonic and Fetal Development; Female; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy | 1994 |
New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Monitoring; Humans; Premedication; Whole-Body Irradiation | 1993 |
Chronic myelogenous leukemia: a review.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cytarabine; Drug Therapy, Combination; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prognosis; Time Factors | 1996 |
[Recent progress in therapy for chronic myelogenous leukemia].
Topics: Age Factors; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1997 |
The biology and treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Survival Analysis | 2001 |
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine | 2001 |
Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Dosage Calculations; Etoposide; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Myeloablative Agonists; Obesity; Transplantation Conditioning | 2014 |
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lenalidomide; Lymphoma, Non-Hodgkin; Methotrexate; Nivolumab; Pemetrexed; Procarbazine; Prospective Studies; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab; Temozolomide; Thiotepa; Vincristine | 2022 |
40 trial(s) available for cytarabine and busulfan
| Article | Year |
|---|---|
Chronic myelogenous leukemia: a clinical and experimental evaluation of splenectomy and intensive chemotherapy.
Topics: Adult; Antineoplastic Agents; Busulfan; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Evaluation Studies as Topic; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Splenectomy; Thioguanine | 1975 |
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lomustine; Male; Middle Aged; Remission Induction; Time Factors | 1992 |
Busulphan, cyclophosphamide, and melphalan as conditioning therapy in allogeneic bone marrow transplants for acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Melphalan; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Whole-Body Irradiation | 1992 |
Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Male; Middle Aged | 1992 |
[Autotransplantation in acute nonlymphoid leukemia].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1991 |
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Busulfan; Clinical Trials as Topic; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lomustine; Male; Middle Aged; Random Allocation; Sex Factors | 1988 |
Busulphan versus combination chemotherapy for initial treatment of chronic granulocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects | 1986 |
Chemotherapy of the myeloid leukaemias.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Busulfan; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Preleukemia; Remission, Spontaneous; Thioguanine | 1980 |
Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Diarrhea; Female; Humans; Leukemia; Loperamide; Male; Middle Aged; Octreotide | 1995 |
Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.
Topics: Anemia, Refractory; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Methotrexate; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Clinical Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Humans; Life Tables; Male; Melphalan; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation, Autologous; Vincristine | 1993 |
Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged | 1995 |
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Middle Aged; Prednisolone; Prognosis; Survival Rate; Transplantation, Autologous; Vincristine | 1996 |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Prognosis; Proportional Hazards Models; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous | 1996 |
Therapeutic trial of intensified conditioning regimen with high-dose cytosine arabinoside, cyclophosphamide and either total body irradiation or busulfan followed by allogeneic bone marrow transplantation for myelodysplastic syndrome in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Humans; Immunosuppressive Agents; Male; Myelodysplastic Syndromes; Transplantation, Homologous; Whole-Body Irradiation | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome | 1997 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 1998 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation | 1998 |
Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Transplantation, Autologous | 1998 |
Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 1998 |
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Prospective Studies; Quinine; Remission Induction; Risk Factors; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Autologous stem cell transplantation for acute myeloid leukemia in first remission.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytapheresis; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous | 2000 |
Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Eye Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Salvage Therapy; Thiotepa | 2001 |
Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Recombinant Proteins; Survival Rate; Treatment Outcome | 2002 |
Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytarabine; Female; Graft vs Host Disease; Humans; Immunophenotyping; Karyotyping; Male; Melphalan; Organophosphates; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2004 |
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cancer Care Facilities; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Eruptions; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Podophyllotoxin; Primary Prevention; Severity of Illness Index; South Australia; Stomatitis; Time Factors; Transplantation Conditioning; Treatment Outcome | 2006 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Eye Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Salvage Therapy; Survival Rate; Thiotepa | 2008 |
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2012 |
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Topics: Adult; Aged; Busulfan; Case-Control Studies; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Prognosis; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Massachusetts; Middle Aged; Rituximab; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2015 |
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Procarbazine; Prognosis; Rituximab; Survival Rate; Thiotepa; Transplantation, Autologous; Vincristine; Young Adult | 2015 |
Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single a
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Disease-Free Survival; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Young Adult | 2015 |
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2016 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Vidarabine; Young Adult | 2019 |
Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study.
Topics: Adult; Busulfan; Cryotherapy; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Stomatitis; Transplantation Conditioning; Young Adult | 2020 |
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Progression-Free Survival; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; United Kingdom; Vidarabine; Young Adult | 2021 |
Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A
Topics: Antilymphocyte Serum; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning | 2023 |
122 other study(ies) available for cytarabine and busulfan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Proliferative capacity of murine hematopoietic stem cells.
Topics: Animals; Busulfan; Cell Differentiation; Cell Division; Cell Survival; Cytarabine; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Male; Mice; Transplantation, Isogeneic | 1978 |
Chemotherapeutic remissions in Wistar Furth rat acute myelogenous leukemia: a model for human AML.
Topics: Animals; Antineoplastic Agents; Busulfan; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Dexamethasone; Disease Models, Animal; Doxorubicin; Leukemia, Experimental; Leukemia, Myeloid, Acute; Methotrexate; Rats; Remission, Spontaneous; Vinblastine; Vincristine | 1977 |
A 13-years remission in chronic myelocytic leukemia after a single course of busulfan.
Topics: Adult; Busulfan; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Remission, Spontaneous; Time Factors | 1978 |
Increased urinary excretion of nucleic acid and nicotinamide derivatives by rats after treatment with alkylating agents.
Topics: 2-Acetylaminofluorene; Alkylating Agents; Animals; Benz(a)Anthracenes; Busulfan; Chromatography, Thin Layer; Cytarabine; Deoxycytidine; Dichlorvos; Dimethylnitrosamine; Ethyl Methanesulfonate; Female; Fluorouracil; Hydrocarbons, Brominated; Mechlorethamine; Methylguanidine; Niacinamide; Nitrosourea Compounds; Rats; Thymidine; Uric Acid | 1975 |
Sister chromatid exchange studies for monitoring DNA damage and repair capacity after cytostatics in vitro and in lymphocytes of leukaemic patients under cytostatic therapy.
Topics: Antineoplastic Agents; Busulfan; Cells, Cultured; Chlorambucil; Chromatids; Crossing Over, Genetic; Cyclophosphamide; Cytarabine; DNA Repair; Erythritol; Humans; Leukemia; Lymphocytes; Mesylates; Mitomycins; Vincristine | 1978 |
[Splenectomy and polychemotherapy in chronic myelosis].
Topics: Busulfan; Cytarabine; Daunorubicin; Humans; Hydroxyurea; Leukemia, Myeloid; Mercaptopurine; Methotrexate; Mitobronitol; Prognosis; Splenectomy; Vincristine | 1979 |
Nature of the hemopoietic stem cell compartment and its proliferative potential.
Topics: Animals; Bone Marrow Cells; Busulfan; Cell Division; Cyclophosphamide; Cytarabine; Fluorouracil; Hematopoietic Stem Cells; Mice; Models, Biological | 1979 |
[Side effects of cytostatic therapy in childhood].
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dactinomycin; Daunorubicin; Female; Fluorouracil; Humans; Male; Mannitol; Mercaptopurine; Methotrexate; Prednisone; Procarbazine; Time Factors; Triaziquone; Vinblastine; Vincristine | 1976 |
The effect of cytosine arabinoside in vitro on agar colony forming cells and spleen colony forming cells of C57BL mouse bone marrow.
Topics: Agar; Animals; Bone Marrow; Bone Marrow Cells; Busulfan; Cell Division; Cell Survival; Cells, Cultured; Cesium Isotopes; Clone Cells; Cytarabine; Femur; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Radiation Effects; Radioisotopes; Spleen; Thymidine; Tritium | 1975 |
Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Transplantation, Homologous | 1992 |
[Second marrow transplantation following high dose busulfan, etoposide, and Ara-C after testicular relapse in a patient with AML].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Testicular Neoplasms | 1992 |
Post consolidation therapy for adult patients with acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1991 |
Comparative effects of busulfan, cytosine arabinoside and adriamycin on different maturation stages of normal human bone marrow cells.
Topics: Bone Marrow; Bone Marrow Cells; Busulfan; Cell Differentiation; Cell Division; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1990 |
Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Drug Evaluation; Humans; Hydroxyurea; Interferons; Leukemia, Myeloid; Prednisone; Recombinant Proteins; Retrospective Studies; Vincristine | 1987 |
Comparison of immunosuppressive agents for prevention of graft rejection in allogeneic bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cytarabine; Etoposide; Graft Rejection; Immunosuppressive Agents; Postoperative Complications; Preoperative Care; Rats; Rats, Inbred Lew; Whole-Body Irradiation | 1989 |
Comparison of cyclophosphamide, cytarabine, and etoposide as immunosuppressive agents before allogeneic bone marrow transplantation.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Radiation; Etoposide; Graft Survival; Immunosuppression Therapy; Rats; Rats, Inbred Strains; Skin Transplantation; Whole-Body Irradiation | 1988 |
Busulfan-induced sideroblastic anemia.
Topics: Anemia, Sideroblastic; Bone Marrow; Busulfan; Chronic Disease; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Middle Aged; Pancytopenia | 1988 |
[Cytogenetic and therapeutic results of a protocol including splenectomy and intensive polychemotherapy in Ph'-positive chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clone Cells; Combined Modality Therapy; Cytarabine; Humans; Leukemia, Myeloid; Philadelphia Chromosome; Prednisone; Splenectomy; Thioguanine; Vincristine | 1986 |
[Treatment of acute adult myeloblastic leukemia with intensive chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Mercaptopurine; Methotrexate; Middle Aged; Mitoguazone; Prednisone; Thioguanine; Vincristine | 1986 |
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Blood Cell Count; Body Weight; Bone Marrow Cells; Busulfan; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Female; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Philadelphia Chromosome; Prednisone; Prognosis; Risk; Vincristine | 1985 |
Busulfan lung complicated by pneumocystis carinii and cytomegalovirus infection.
Topics: Busulfan; Cytarabine; Cytomegalovirus Infections; Female; Humans; Leukemia, Myeloid; Lung; Middle Aged; Pneumonia, Pneumocystis; Prednisone; Pulmonary Fibrosis | 1974 |
An experimental study on the significance of the bone marrow lymphocyte in haematopoietic regeneration following acute injury due to 60CO irradiation and cytotoxic drugs.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Busulfan; Cobalt Radioisotopes; Cytarabine; Hematopoietic System; Hydroxyurea; Lymph Nodes; Lymphocytes; Male; Microscopy, Electron; Radiation Dosage; Radiation Injuries; Rats; Regeneration; Spleen; Thymus Gland | 1974 |
The generation time of human leukemic myeloblasts.
Topics: Aged; Autoradiography; Bone Marrow; Bone Marrow Cells; Busulfan; Cell Division; Cytarabine; DNA, Neoplasm; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prednisolone; Thymidine; Time Factors; Tritium | 1972 |
Decreased leukocyte alkaline phosphatase in monocytic leukemia.
Topics: Aged; Alkaline Phosphatase; Anemia; Blood Transfusion; Bone Marrow; Busulfan; Cytarabine; Female; Histocytochemistry; Humans; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Pneumonia; Purpura; Radiography; Sepsis; Splenomegaly; Staphylococcal Infections; Tetracycline; Thioguanine | 1972 |
[Clinical studies on the early diagnosis and treatment of blastic crisis of chronic myelogenous leukemia].
Topics: Alkaline Phosphatase; Busulfan; C-Reactive Protein; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone | 1972 |
Cytogenetic studies during remission of blastic crisis in a patient with chronic myelocytic leukaemia.
Topics: Adult; Aneuploidy; Blood Cell Count; Blood Platelets; Busulfan; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Cytarabine; Erythrocytes, Abnormal; Female; Hematocrit; Humans; Leukemia, Myeloid; Leukocyte Count; Remission, Spontaneous | 1973 |
Management of priapism in patients with chronic granulocytic leukemia.
Topics: Adult; Anti-Bacterial Agents; Busulfan; Cytarabine; Diazepam; Humans; Hydroxyurea; Infusions, Parenteral; Leukemia, Myeloid; Male; Priapism; Splenomegaly | 1974 |
Mediastinal adenopathy in granulocytic leukemia.
Topics: Adult; Busulfan; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Lymph Nodes; Lymphoma; Male; Mediastinal Neoplasms; Thioguanine | 1974 |
Blood and neoplastic diseases. Rational approach to the chemotherapy of human malignant disease-II.
Topics: Antineoplastic Agents; Brain Neoplasms; Busulfan; Cell Count; Cell Division; Cytarabine; Diffusion; Drug Tolerance; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukocyte Count; Lymphoma; Methotrexate; Multiple Myeloma; Neoplasms; Vincristine | 1974 |
[Our experience in the treatment of acute myeloblastic leukemia].
Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Thioguanine; Vincristine | 1974 |
[Chemotherapy of cancer. Hints for continuing medical education].
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Education, Medical, Continuing; Fluorouracil; Humans; Melphalan; Mercaptopurine; Methotrexate; Neoplasms; Procarbazine; Triaziquone; Vinblastine; Vincristine | 1974 |
Cell proliferation and the differential response of normal and malignant tissues. Silvanus Thompson Memorial Lecture.
Topics: Animals; Blood Vessels; Busulfan; Cell Survival; Cyclophosphamide; Cytarabine; Diffusion; Epithelial Cells; Epithelium; Fibrosarcoma; Hematopoietic Stem Cells; Intestine, Small; Leukemia L1210; Leukemia, Experimental; Methotrexate; Mice; Mitosis; Necrosis; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Oxygen; Radiation Effects; Rats | 1972 |
Drugs in the treatment of leukemia.
Topics: Asparaginase; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Humans; Hydroxyurea; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Pipobroman; Prednisolone; Vincristine | 1968 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Prednisone; Vincristine | 1970 |
Chemotherapy-induced changes in serum vitamin B 12 binding proteins in myeloid leukemia.
Topics: Antineoplastic Agents; Asparaginase; Busulfan; Chromatography, Ion Exchange; Cobalt Isotopes; Cytarabine; Humans; Leukemia, Myeloid; Leukocyte Count; Mercaptopurine; Protein Binding; Serum Globulins; Vitamin B 12 | 1971 |
[Results of cytostatic and radiologic treatment of chronic myelocytic leukemia (analysis of 11 cases)].
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Examination; Busulfan; Cytarabine; Female; Humans; Leukemia, Myeloid; Leukocytosis; Male; Mannitol; Mercaptopurine; Middle Aged; Nitrosourea Compounds; Prednisone; Remission, Spontaneous; Splenic Neoplasms; Splenomegaly; Vincristine | 1970 |
Long-term survival of patients with Burkitt's lymphoma: an assessment of treatment and other factors which may relate to survival.
Topics: Adolescent; Antineoplastic Agents; Burkitt Lymphoma; Busulfan; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Cytarabine; Female; Humans; Immunotherapy; Infant; Kenya; Male; Mannitol; Melphalan; Methotrexate; Nitrogen Mustard Compounds; Nitroso Compounds; Urea | 1967 |
Treatment of myeloid blastic crisis of chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid; Prednisone; Transplantation, Autologous; Vincristine | 1984 |
Studies on micronuclei time response and on the effects of multiple treatments of mutagens on induction of micronuclei.
Topics: Animals; Busulfan; Cell Nucleus; Colchicine; Cyclophosphamide; Cytarabine; Ethyl Methanesulfonate; Floxuridine; Male; Methotrexate; Methyl Methanesulfonate; Mice; Mitomycins; Mutagenicity Tests; Mutagens; Time Factors; Triethylenemelamine; Vincristine | 1981 |
Busulfan, antimetabolites, radiotherapy, and cost of treatment in chronic myelocytic leukemia. A non-controlled, non-randomized monocenter study with historical controls.
Topics: Busulfan; Costs and Cost Analysis; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid; Radiography; Spleen; Thioguanine | 1981 |
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marrow Transplantation; Busulfan; Carmustine; Cells, Cultured; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Susceptibility; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Monocytes; Neopterin; Podophyllotoxin; Respiratory Burst; Superoxides; Tumor Necrosis Factor-alpha; Whole-Body Irradiation | 1995 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Leukemia; Lung Diseases, Interstitial; Male; Methylprednisolone; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Tissue Donors; Treatment Outcome; Whole-Body Irradiation; Wisconsin | 1995 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Bone marrow transplantation in Iran.
Topics: Adolescent; Adult; Anemia, Aplastic; beta-Thalassemia; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Financing, Personal; Graft vs Host Disease; Humans; Insurance, Health, Reimbursement; Iran; Lymphoma; Male; Melphalan; Middle Aged; Transplantation, Autologous; Transplantation, Homologous | 1994 |
Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclosporine; Cytarabine; Drug Therapy, Combination; Graft Rejection; Histocompatibility; HLA Antigens; Humans; Incidence; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Tissue Donors | 1994 |
Combination of chemotherapy and interferon alfa-2b in the treatment of chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Remission Induction | 1993 |
Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Plateletpheresis; Remission Induction; Retrospective Studies; Thrombocytosis | 1993 |
Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Hematopoiesis; Hematopoietic Stem Cells; Leukocyte Count; Male; Mice; Mice, Inbred C3H; Time Factors; Whole-Body Irradiation | 1993 |
Recovery from diabetes insipidus associated with AML after a BMT conditioning regimen including busulfan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cytarabine; Daunorubicin; Deamino Arginine Vasopressin; Diabetes Insipidus; Humans; Incidence; Leukemia, Myelomonocytic, Acute; Male; Remission Induction | 1993 |
Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Infant; Japan; Leukemia; Male; Methotrexate; Nimustine; Proportional Hazards Models; Radiotherapy Dosage; Remission Induction; Transplantation, Homologous; Whole-Body Irradiation | 1993 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Bone Marrow; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Epidural Space; Fatal Outcome; Frontal Bone; Humans; Leukemia, Myeloid; Leukemic Infiltration; Male; Methylprednisolone; Spinal Canal; Thrombocythemia, Essential | 1996 |
Association of busulfan area under the curve with veno-occlusive disease following BMT.
Topics: Adolescent; Adult; Aged; Bone Marrow Transplantation; Busulfan; Circadian Rhythm; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Retrospective Studies; Risk | 1996 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Time Factors | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon-alpha; Lenograstim; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Recombinant Proteins; Treatment Outcome | 1998 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |
[Interferon-alpha in the treatment of chronic myeloid leukemia].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cause of Death; Cytarabine; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome | 1999 |
Multifocal reversible epithelial dysplasia mimicking carcinoma in situ after conditioning therapy with busulfan and cyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carcinoma in Situ; Cyclophosphamide; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Monocytic, Acute; Mitoxantrone; Remission Induction; Thioguanine; Transplantation, Autologous; Uterine Cervical Dysplasia | 1999 |
[Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia].
Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dilatation; Esophageal Stenosis; Esophagitis; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Transplantation Conditioning; Ulcer | 1999 |
Total body irradiation before allogeneic bone marrow transplantation: is more dose better?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2001 |
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2001 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; Cytarabine; Down Syndrome; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Thioguanine; Vincristine | 2002 |
Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Component Removal; Bone Marrow Purging; Busulfan; Cytarabine; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Hydroxyurea; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Neoplastic Cells, Circulating; Pain; Philadelphia Chromosome; Recombinant Proteins; Remission Induction; Safety; Transplantation, Autologous; Treatment Outcome | 2002 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Autologous stem cell transplantation for advanced acute myeloid leukemia.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Count; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Cytogenetics; Disease-Free Survival; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Translocation, Genetic; Transplantation, Autologous | 2002 |
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modality Therapy; Consciousness Disorders; Cytarabine; Drug Resistance, Multiple; Enzyme Inhibitors; Fatal Outcome; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunosuppressive Agents; Indomethacin; Infarction; Male; Middle Aged; Mitral Valve Stenosis; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Splenectomy | 2002 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Models, Biological; Peripheral Blood Stem Cell Transplantation; Remission Induction; Risk; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Eye Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, T-Cell; Middle Aged; Prognosis; Recurrence; Thiotepa | 2004 |
[Modulating effect of antileukemia drugs on the cellular susceptibility in chronic myeloid leukemia to cytotoxic lymphocytes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Humans; Hydroxyurea; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear | 2006 |
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Sensitivity of mesenchymal stem cells and their progeny to medicines used for the treatment of hematoproliferative diseases.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Busulfan; Cyclophosphamide; Cytarabine; Female; Fibroblasts; Mesenchymal Stem Cells; Methotrexate; Mice; Mice, Inbred Strains; Pyrazines; Stromal Cells | 2008 |
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cytarabine; Daunorubicin; Etoposide; Female; fms-Like Tyrosine Kinase 3; Genes, Wilms Tumor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Prognosis; Proportional Hazards Models; Statistics, Nonparametric | 2008 |
Mucoepidermoid carcinoma of the submandibular gland after chemotherapy in a child.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Busulfan; Carcinoma, Mucoepidermoid; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Image Processing, Computer-Assisted; Leukemia, Myeloid, Acute; Male; Neck Dissection; Neoplasms, Second Primary; Positron-Emission Tomography; Submandibular Gland Neoplasms; Thioguanine; Tomography, X-Ray Computed; Transplantation Conditioning | 2009 |
[Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Mechlorethamine; Methylprednisolone; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Prednisone; PUVA Therapy; Recombinant Proteins; Remission Induction; Tetrahydronaphthalenes; Transplantation, Autologous; Vincristine | 2008 |
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous | 2008 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Infections; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Postoperative Complications; Recurrence; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Salvage Therapy; Thiotepa; Young Adult | 2011 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carboplatin; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant; Male; Melphalan; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neuroblastoma; Peripheral Blood Stem Cell Transplantation; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Vidarabine; Vincristine | 2011 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carmustine; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Salvage Therapy; Stem Cell Transplantation; Thiotepa; Vincristine; Young Adult | 2013 |
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Retrospective Studies; Standard of Care; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2013 |
Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Busulfan; Chromosome Mapping; Cytarabine; Disease-Free Survival; DNA; Etoposide; Female; Follow-Up Studies; Genetic Loci; Genotype; Glutathione Transferase; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Membrane Transport Proteins; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Proportional Hazards Models; Remission Induction; Young Adult | 2013 |
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2013 |
Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Female; Follow-Up Studies; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Melphalan; Neoplasm Recurrence, Local; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2014 |
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2014 |
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fibrinogen; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning; Young Adult | 2014 |
[Comparing BFA with BuCyA as a myeloablative conditioning regimen for allogeneic stem cell transplantation in acute leukemias].
Topics: Acute Disease; Busulfan; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2015 |
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Matched-Pair Analysis; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2015 |
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Middle Aged; Mycophenolic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
[Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; China; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Incidence; Male; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2016 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Histocompatibility; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Cytarabine; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Methotrexate; Middle Aged; Mucositis; Remission Induction; Retrospective Studies; Rituximab; Stem Cell Transplantation; Temozolomide; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2017 |
A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Cystitis; Cytarabine; Cytomegalovirus Infections; Drug Therapy, Combination; Epstein-Barr Virus Infections; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Leukocytes; Male; Prospective Studies; Transplantation Conditioning; Young Adult | 2018 |
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning | 2019 |
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult | 2019 |
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cytarabine; Female; France; Humans; Lymphoma; Male; Melphalan; Middle Aged; Mucositis; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2019 |
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2019 |
Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2020 |
Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
Topics: Adult; Busulfan; Cladribine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Melphalan; Mitoxantrone; Salvage Therapy; Transplantation Conditioning | 2020 |
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2020 |
Personalized prediction of overall survival in patients with AML in non-complete remission undergoing allo-HCT.
Topics: Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Karnofsky Performance Status; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Nomograms; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2022 |
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Cocktail Conditioning Regimen for the Treatment of Pediatric Patients with Chronic Active Epstein-Barr Virus: A Retrospective Observational Study.
Topics: Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Epstein-Barr Virus Infections; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water | 2022 |
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Recurrence; Retrospective Studies | 2023 |
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Retrospective Studies; Transplantation Conditioning | 2023 |
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Melphalan; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2023 |